Roche to Invest 50 Billion Dollars in Pharmaceuticals, Diagnostics in the USA

US Investments Roche to Invest 50 Billion Dollars in Pharmaceuticals, Diagnostics in the USA

2025-04-23 Source: Press release Roche 2 min Reading Time

Related Vendors

Roche Diagnostics Deutschland GmbH

Turck_Your_Global_Automation_Partner.jpg ()

TURCK GmbH

Italvacuum, Srl

Donadon SDD Srl

Over the next five years, Roche has plans to invest a whopping amount of 50 billion dollars in pharmaceuticals and diagnostics in the United States of America. With this move, the company intends to increase its existing footprint of more than 25,000 employees in 24 sites across eight US states.

Roche has recently announced that it will invest 50 billion dollars into the United States of America in the next five years.(Source: Pixabay) — Roche has recently announced that it will invest 50 billion dollars into the United States of America in the next five years.
(Source: Pixabay)

Basel/Switzerland – Roche has recently announced that it will invest 50 billion dollars into the United States of America in the next five years. These investments further strengthen Roche’s already significant US footprint with 13 manufacturing and 15 R&D sites across the Pharmaceutical and Diagnostics Divisions, and are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities.

As part of this investment, Roche will increase its existing footprint of more than 25,000 employees in 24 sites across eight US states. The investment will include:

Expanded and upgraded US manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon and California

A state-of-the-art gene therapy manufacturing facility in Pennsylvania

A new 900,000 square foot manufacturing centre to support Roche’s expanding portfolio of next generation weight loss medicines (location to be announced)

A new manufacturing facility for continuous glucose monitoring in Indiana

A new R&D centre in Massachusetts, conducting cutting-edge artificial intelligence (AI) research and serving as hub for its new cardiovascular, renal and metabolism research and development efforts

Significant expansion and upgrading of its existing pharmaceuticals and diagnostics R&D centres in Arizona, Indiana and California

“Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the US,” said Thomas Schinecker, Roche Group CEO. “We are proud of our 110-year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions. Our investments of 50 billion dollars over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and a

round the world.”

Once all new and expanded manufacturing capacity comes on-line, Roche will export more medicines from the US than it imports. Today, its diagnostics division already has an export surplus from the US to other countries.

(ID:50397611)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.